Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti-infection products, such as fosfomycin series, azithromycin series, amantadine series, berberine hydroch… Read more
Northeast Pharmaceutical Group Co Ltd (000597) - Total Assets
Latest total assets as of September 2025: CN¥13.65 Billion CNY
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) holds total assets worth CN¥13.65 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Northeast Pharmaceutical Group Co Ltd - Total Assets Trend (1993–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Northeast Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Northeast Pharmaceutical Group Co Ltd's total assets of CN¥13.65 Billion consist of 59.9% current assets and 40.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 30.9% |
| Accounts Receivable | CN¥2.69 Billion | 18.6% |
| Inventory | CN¥1.32 Billion | 9.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.41 Billion | 9.7% |
| Goodwill | CN¥154.45 Million | 1.1% |
Asset Composition Trend (1993–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Northeast Pharmaceutical Group Co Ltd's current assets represent 59.9% of total assets in 2024, an increase from 53.5% in 1993.
- Cash Position: Cash and equivalents constituted 30.9% of total assets in 2024, up from 1.7% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 2.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 18.6% of total assets.
Northeast Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Northeast Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Northeast Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Northeast Pharmaceutical Group Co Ltd generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Northeast Pharmaceutical Group Co Ltd generates $ 2.84 in net profit.
Northeast Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.11 | 1.07 | 0.76 |
| Quick Ratio | 0.96 | 0.92 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥846.62 Million | CN¥ 612.20 Million | CN¥ -1.76 Billion |
Northeast Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Northeast Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | CN¥14.45 Billion |
| Market Capitalization | $425.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Northeast Pharmaceutical Group Co Ltd's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Northeast Pharmaceutical Group Co Ltd's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Northeast Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual total assets of Northeast Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥14.45 Billion | -5.42% |
| 2023-12-31 | CN¥15.27 Billion | +10.60% |
| 2022-12-31 | CN¥13.81 Billion | +4.79% |
| 2021-12-31 | CN¥13.18 Billion | +8.33% |
| 2020-12-31 | CN¥12.17 Billion | -2.98% |
| 2019-12-31 | CN¥12.54 Billion | +7.01% |
| 2018-12-31 | CN¥11.72 Billion | +10.63% |
| 2017-12-31 | CN¥10.59 Billion | +8.20% |
| 2016-12-31 | CN¥9.79 Billion | +12.62% |
| 2015-12-31 | CN¥8.69 Billion | +1.40% |
| 2014-12-31 | CN¥8.57 Billion | +13.48% |
| 2013-12-31 | CN¥7.55 Billion | +26.05% |
| 2012-12-31 | CN¥5.99 Billion | +2.06% |
| 2011-12-31 | CN¥5.87 Billion | +4.76% |
| 2010-12-31 | CN¥5.61 Billion | -7.78% |
| 2009-12-31 | CN¥6.08 Billion | +48.12% |
| 2008-12-31 | CN¥4.10 Billion | +34.50% |
| 2007-12-31 | CN¥3.05 Billion | +38.22% |
| 2006-12-31 | CN¥2.21 Billion | -3.93% |
| 2005-12-31 | CN¥2.30 Billion | -5.61% |
| 2004-12-31 | CN¥2.43 Billion | -3.47% |
| 2003-12-31 | CN¥2.52 Billion | -5.94% |
| 2002-12-31 | CN¥2.68 Billion | -2.72% |
| 2001-12-31 | CN¥2.76 Billion | +3.25% |
| 2000-12-31 | CN¥2.67 Billion | +2.61% |
| 1999-12-31 | CN¥2.60 Billion | +0.43% |
| 1998-12-31 | CN¥2.59 Billion | +19.59% |
| 1997-12-31 | CN¥2.17 Billion | -30.07% |
| 1996-12-31 | CN¥3.10 Billion | +26.30% |
| 1995-12-31 | CN¥2.45 Billion | +53.45% |
| 1994-12-31 | CN¥1.60 Billion | +6.29% |
| 1993-12-31 | CN¥1.50 Billion | -- |